Last reviewed · How we verify
individualized anti-tumor new antigen iNeo-Vac-R01 injection
individualized anti-tumor new antigen iNeo-Vac-R01 injection is a Biologic drug developed by Zhejiang University. It is currently in Phase 1 development.
iNeo-Vac-R01 is a personalized neoantigen mRNA therapy in development by Zhejiang University for advanced cancers, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic cancer. Currently in Phase 1 and 2 trials, the therapy aims to enhance the immune response against tumor-specific antigens.
At a glance
| Generic name | individualized anti-tumor new antigen iNeo-Vac-R01 injection |
|---|---|
| Sponsor | Zhejiang University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- individualized anti-tumor new antigen iNeo-Vac-R01 injection CI brief — competitive landscape report
- individualized anti-tumor new antigen iNeo-Vac-R01 injection updates RSS · CI watch RSS
- Zhejiang University portfolio CI
Frequently asked questions about individualized anti-tumor new antigen iNeo-Vac-R01 injection
What is individualized anti-tumor new antigen iNeo-Vac-R01 injection?
individualized anti-tumor new antigen iNeo-Vac-R01 injection is a Biologic drug developed by Zhejiang University.
Who makes individualized anti-tumor new antigen iNeo-Vac-R01 injection?
individualized anti-tumor new antigen iNeo-Vac-R01 injection is developed by Zhejiang University (see full Zhejiang University pipeline at /company/zhejiang-university).
What development phase is individualized anti-tumor new antigen iNeo-Vac-R01 injection in?
individualized anti-tumor new antigen iNeo-Vac-R01 injection is in Phase 1.